Johnson & Johnson Reserves Funds for Settlement

In a June 8, 2012 press release, Johnson & Johnson stated it is taking a $600 million charge for settlement of cases involving J&J kickbacks to long term care pharmacy chain Omnicare to increase sales of Risperdal and two other drugs. VS&G represents the whistleblower in one of the two qui tam cases against J&J for paying kickbacks to Omnicare to promote Risperdal.

Read the New York Times Story